309 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28089699	63	Investigation of piperazine benzamides as humanß	Merck
28523097	37	Similarity- and Substructure-Based Development ofß	Philipps University Marburg
27876250	60	Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH	Jagiellonian University Medical College
27839919	192	Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples.	University of Kansas
27132867	154	Structure-guided development of dualß2 adrenergic/dopamine D2 receptor agonists.	Friedrich-Alexander University
26988801	55	Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.	Jagiellonian University Medical College
26704965	229	Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.	University of Illinois At Chicago
26709102	142	Discovery of Vibegron: A Potent and Selectiveß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.	Merck Research Laboratories
26471092	23	Molecular hybridization yields triazole bronchodilators for the treatment of COPD.	Pfizer
26125514	40	Discovery of Novel Indazole Derivatives as Highly Potent and Selective Humanß3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.	Asahi Kasei Pharma
25695425	62	Semisynthetic Studies on and Biological Evaluation of N-Methyllaurotetanine Analogues as Ligands for 5-HT Receptors.	City University of New York
25629394	52	Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist..	Theravance Biopharma
25592716	6	Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting theß2 adrenoceptor.	Instituto Polit£Cnico Nacional (Ipn)
25065493	92	The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-actingß2-adrenoceptor agonist.	Novartis Institutes For Biomedical Research
24881566	140	Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).	Glaxosmithkline
25241924	47	The design and implementation of a generic lipopeptide scanning platform to enable the identification of 'locally acting' agonists for the apelin receptor.	Novartis Institutes For Biomedical Research
24835980	98	Discovery of TD-4306, a long-actingß2-agonist for the treatment of asthma and COPD.	Theravance
24878222	50	Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors.	Pfizer
24813741	110	Multivalent design of long-actingß(2)-adrenoceptor agonists incorporating biarylamines.	Theravance
24900851	6	Discovery of AZD3199, An Inhaled Ultralong Acting?2 Receptor Agonist with Rapid Onset of Action.	Astrazeneca
16640337	47	Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.	Glaxosmithkline
2870189	11	Quantitative evaluation of the beta 2-adrenoceptor intrinsic activity of N-tert-butylphenylethanolamines.	TBA
24300734	12	Design, synthesis and evaluation of dual pharmacologyß2-adrenoceptor agonists and PDE4 inhibitors.	Sun Yat-Sen University
23614528	121	Synthesis and in vitro and in vivo characterization of highlyß1-selectiveß-adrenoceptor partial agonists.	University of Nottingham
21870877	119	Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-labeled fluorescent ligands for humanß-adrenoceptors.	University of Nottingham
11806709	63	Synthesis and evaluation of potent and selective beta(3) adrenergic receptor agonists containing acylsulfonamide, sulfonylsulfonamide, and sulfonylurea carboxylic acid isosteres.	Glaxosmithkline
1346651	29	Synthesis of halogenated trimetoquinol derivatives and evaluation of their beta-agonist and thromboxane A2 (TXA2) antagonist activities.	Ohio State University
2993621	68	Quantitative evaluation of the beta 2-adrenoceptor affinity of phenoxypropanolamines and phenylethanolamines.	TBA
22932315	28	An investigation into the structure-activity relationships associated with the systematic modification of theß(2)-adrenoceptor agonist indacaterol.	Novartis Institutes For Biomedical Research
22079756	219	From libraries to candidate: the discovery of new ultra long-acting dibasicß2-adrenoceptor agonists.	Astrazeneca
22178551	46	A multivalent approach to the discovery of long-actingß(2)-adrenoceptor agonists for the treatment of asthma and COPD.	Theravance
21925889	48	The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating a urea group.	Glaxosmithkline
21696967	51	The discovery of long-acting saligeninß2 adrenergic receptor agonists incorporating hydantoin or uracil rings.	Glaxosmithkline
21723724	91	Design-driven LO: the discovery of new ultra long acting dibasicß2-adrenoceptor agonists.	Astrazeneca
21652207	17	Design driven HtL: The discovery and synthesis of new high efficacyß2-agonists.	Astrazeneca
20462258	50	Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.	Glaxosmithkline
19317397	62	Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating arylsulfonamide groups.	Glaxosmithkline
19146417	70	The discovery of a selective, small molecule agonist for the MAS-related gene X1 receptor.	Glaxosmithkline
18433113	124	Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists.	Glaxosmithkline
11311067	38	Discovery of novel N-phenylglycine derivatives as potent and selective beta(3)-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence.	Kissei Pharmaceutical
9548813	53	The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.	Smithkline Beecham Pharmaceuticals
6330358	6	The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite.	TBA
6148422	36	Synthesis and beta-adrenergic blocking activity of new aliphatic and alicyclic oxime ethers.	TBA
6134834	54	Beta 1-selective adrenoceptor antagonists: examples of the 2-[4-[3-(substituted-amino)-2-hydroxypropoxy]phenyl]imidazole class.	TBA
6130154	68	Ultra-short-acting beta-adrenergic receptor blocking agents. 2. (Aryloxy)propanolamines containing esters on the aryl function.	TBA
6130153	66	Ultra-short-acting beta-adrenergic receptor blocking agents. 1. (Aryloxy)propanolamines containing esters in the nitrogen substituent.	TBA
6120237	15	2-Benzodioxinylaminoethanols: a new class of beta-adrenergic blocking and antihypertensive agents.	TBA
6104730	47	Synthesis and beta-adrenergic blocking activity of new aliphatic oxime ethers.	TBA
11454468	35	Discovery and SAR of org 24598-a selective glycine uptake inhibitor.	Organon Research and Development Group
21486038	177	Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.	H. Lundbeck
23641311	38	From a4ß2 Nicotinic Ligands to the Discovery of s1 Receptor Ligands: Pharmacophore Analysis and Rational Design.	TBA
22563707	27	A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design.	Radboud University Nijmegen Medical Centre
22313227	78	Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.	National Institute of Mental Health
24900353	6	Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.	TBA
21207959	69	Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.	National Institute of Mental Health
20875743	90	Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela	Pfizer
20684563	176	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.	H. Lundbeck
20181479	177	Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic profiles.	Merck Research Laboratories
19963380	38	Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.	Hunter College and The Graduate Center of The City University of New York
19821575	47	Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues.	Glaxosmithkline
19608416	29	Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.	Astellas Pharma
19168263	14	Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.	Instituto Polit£Cnico Nacional (Ipn)
19581100	162	Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.	Astellas Pharma
19232786	72	Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.	Astellas Pharma
18651730	123	Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.	Astellas Pharma
18307290	97	Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.	Astellas Pharma
17897826	18	The discovery of indole-derived long acting beta2-adrenoceptor agonists for the treatment of asthma and COPD.	Pfizer
17845020	44	Nitric oxide donor beta2-agonists: furoxan derivatives containing the fenoterol moiety and related furazans.	Universit£
17498952	4	The discovery of long acting beta2-adrenoreceptor agonists.	Pfizer
16451077	86	Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.	Pfizer
16198561	99	Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.	Novartis Institutes For Biomedical Research
16250647	71	2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.	Universit£
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
15603933	28	Discovery of a novel, potent and selective human beta3-adrenergic receptor agonist.	Fujisawa Pharmaceutical
15324892	9	Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity.	Novartis Horsham Research Centre
12502364	17	Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.	Kissei Pharmaceutical
12213075	70	Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).	Purdue University
11311069	64	(4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists.	Wyeth-Ayerst Research
8691440	22	Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic.	University of Pennsylvania
7562902	114	Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.	Smithkline Beecham Pharmaceuticals
7658429	31	(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).	Abbott Laboratories
8254623	54	Syntheses of 2,5- and 2,6-difluoronorepinephrine, 2,5-difluoroepinephrine, and 2,6-difluorophenylephrine: effect of disubstitution with fluorine on adrenergic activity.	National Institute of Diabetes and Digestive and Kidney Diseases
8230093	34	Conformationally restrained analogs of sympathomimetic catecholamines. Synthesis, conformational analysis, and adrenergic activity of isochroman derivatives.	Universit£
1313109	40	Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic receptors.	Universit£
1359141	47	Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines.	Merck Sharp and Dohme Research Laboratories
1833546	47	Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands.	Abbott Laboratories
2319556	16	Synthesis and pharmacological studies of N-[4-[2-hydroxy-3-[[2-[4-(1H-imidazol-1- yl)phenoxy]ethyl]amino]propoxy]phenyl]methanesulfonamide, a novel antiarrhythmic agent with class II and class III activities.	Berlex Laboratories
1976812	62	Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity.	Berlex Laboratories
2213824	20	Thiazole as a carbonyl bioisostere. A novel class of highly potent and selective 5-HT3 receptor antagonists.	Pfizer
6126588	12	Use of (S)-(trifloxymethyl)oxirane in the synthesis of a chiral beta-adrenoceptor antagonist, (R)- and (S)-9-[[3-(tert-butylamino)-2-hydroxypropyl]oximino]fluorene.	TBA
15203136	39	(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.	Virginia Commonwealth University
	8	Synthesis and pharmacological characterization of A-80426: A putative novel antidepressant combining -2 antagonism with 5-HT uptake inhibition	TBA
22297114	20	Dualß2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.	Sun Yat-Sen University
22182578	13	Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the humanß2-adrenoceptor.	Instituto Polit£Cnico Nacional (Ipn)
21863888	9	Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-ß2-agonist for the treatment of chronic obstructive pulmonary disease.	Pfizer
21783363	10	Synthesis and in vitro evaluation of derivatives of theß¿?-adrenergic receptor antagonist HX-CH 44.	University of Toronto
21591752	41	Identification of N-propylnoraporphin-11-yl 5-(1,2-dithiolan-3-yl)pentanoate as a new anti-Parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.	Soochow University College of Pharmaceutical Sciences
20036561	39	Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.	Medical University of Lublin
21615150	14	Progress in structure based drug design for G protein-coupled receptors.	Heptares Therapeutics
21075627	26	Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.	Pfizer
21353541	25	Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective humanß3 adrenergic receptor agonists.	Merck Research Laboratories
21310610	63	Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.	Theravance
21277205	26	Discovery of substituted phenyl urea derivatives as novel long-actingß2-adrenoreceptor agonists.	RhôNe-Poulenc Rorer
24900301	24	Discovery of a Potent and Short−Acting Oral Calcilytic with a Pulsatile Secretion of Parathyroid Hormone	TBA
20833036	221	Thienopyrimidines asß3-adrenoceptor agonists: hit-to-lead optimization.	4Sc
20812727	157	Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for positron emission tomography.	National Institute of Mental Health
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical and Public Health Institute
20804199	23	Inhalation by design: novel ultra-long-actingß(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.	Pfizer
20655218	72	A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.	Novartis Institutes For Biomedical Research
20620058	41	Smoothened antagonists for hair inhibition.	Pfizer
20591666	66	A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.	Università
20434333	111	A vHTS approach for the identification of beta-adrenoceptor ligands.	4Sc
20402514	34	The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.	Novartis Institutes For Biomedical Research
20384344	42	Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.	Meiji Seika Kaisha
20096576	41	Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.	Boehringer Ingelheim Pharma
19857969	6	Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines.	National Institute of Diabetes and Digestive and Kidney Diseases
19646882	72	Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.	University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and The Informatics Institute of Umdnj
19646865	45	Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.	Pfizer
19643607	26	Studies towards topical selective beta2-adrenoceptor agonists with a long duration of action.	Boehringer Ingelheim Pharma
19875286	44	Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.	Boehringer Ingelheim Pharma
	38	Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivity	TBA
	26	BMS-187257, a potent, selective, and novel heterocyclic β3 adrenergic receptor agonist	TBA
	3	Asymmetric synthesis of FR165914: A novel β3-adrenergic agonist with a benzocycloheptene structure	TBA
19492813	56	Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.	Glaxosmithkline
19366244	138	Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.	Astellas Pharma
19362005	74	Synthesis and evaluation of novel phenoxypropanolamine derivatives containing acetanilides as potent and selective beta3-adrenergic receptor agonists.	Astellas Pharma
19081260	10	Substituted 1,2,3,4-tetrahydroquinolin-6-yloxypropanes as beta3-adrenergic receptor agonists: design, synthesis, biological evaluation and pharmacophore modeling.	Central Drug Research Institute
18829308	5	Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.	Lundbeck Research Usa
18656910	2	Facile radiosynthesis of fluorine-18 labeled beta-blockers. Synthesis, radiolabeling, and ex vivo biodistribution of [18F]-(2S and 2R)-1-(1-fluoropropan-2-ylamino)-3-(m-tolyloxy)propan-2-ol.	Centre For Addiction and Mental Health
18573659	47	Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.	Glaxosmithkline
18553954	126	Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.	Astellas Pharma
18507369	85	Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide.	Theravance
18180157	10	Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains.	St. Jude Children'S Research Hospital
17911024	37	Potent oxindole based human beta3 adrenergic receptor agonists.	Eli Lilly
17804228	44	Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.	Eli Lilly
17632003	55	Discovery of potent and orally bioavailable heterocycle-based beta3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity.	Pfizer
17571866	49	Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.	National Institute of Mental Health
17533126	78	Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.	Bristol-Myers Squibb Pharmaceutical Research Institute
17524641	69	3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.	Glaxosmithkline
17506540	52	Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.	Medical University of Lublin
17303428	22	Novel chiral isoxazole derivatives: synthesis and pharmacological characterization at human beta-adrenergic receptor subtypes.	Università
16931005	21	Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.	Eli Lilly
16392798	46	Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.	Columbia University College of Physicians and Surgeons
15686912	35	Tryptamine-based human beta3-adrenergic receptor agonists. Part 3: improved oral bioavailability via modification of the sulfonamide moiety.	Dainippon Pharmaceutical
15546708	35	Tryptamine-based human beta3-adrenergic receptor agonists. Part 2: SAR of the methylene derivatives.	Dainippon Pharmaceutical
15546707	60	Tryptamine-based human beta3-adrenergic receptor agonists. Part 1: SAR studies of the 7-position of the indole ring.	Dainippon Pharmaceutical
14643338	124	Binding of beta-carbolines at 5-HT(2) serotonin receptors.	Virginia Commonwealth University
12873495	2	Synthesis and preliminary evaluation of (R,R)(S,S) 5-(2-(2-[4-(2-[(18)F]fluoroethoxy)phenyl]-1-methylethylamino)-1-hydroxyethyl)-benzene-1,3-diol ([(18)F]FEFE) for the in vivo visualisation and quantification of the beta2-adrenergic receptor status in lung.	University of Mainz
12798332	35	Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists.	Wyeth Research
12657269	52	Novel and potent human and rat beta3-adrenergic receptor agonists containing substituted 3-indolylalkylamines.	Dainippon Pharmaceutical
12361399	17	Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding.	Universita Di Camerino
12270184	34	Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 2: arylethanolaminomethylpiperidines.	Wyeth Research
12270183	45	Novel substituted 4-aminomethylpiperidines as potent and selective human beta3-agonists. Part 1: aryloxypropanolaminomethylpiperidines.	Wyeth Research
32686936	8	Photoswitchable Antagonists for a Precise Spatiotemporal Control of ?	Institute For Advanced Chemistry of Catalonia (Iqac-Csic)
11327605	27	New oxadiazolidinedione derivatives as potent and selective human beta3 agonists.	Wyeth-Ayerst Research
11277513	25	2,4-Thiazolidinediones as potent and selective human beta3 agonists.	Wyeth-Ayerst Research
11212115	72	Human beta3 adrenergic receptor agonists containing cyanoguanidine and nitroethylenediamine moieties.	Merck Research Laboratories
31753798	49	Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent ?	Shenyang Pharmaceutical University
11055339	59	Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human beta3 adrenergic receptor agonists.	Merck Research Laboratories
11052788	33	Discovery of a potent, orally bioavailable beta(3) adrenergic receptor agonist, (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4 -[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide.	Merck Research Laboratories
10999482	52	Human beta3-adrenergic receptor agonists containing 1,2,3-triazole-substituted benzenesulfonamides.	Merck Research Laboratories
10987429	69	Potent, selective 3-pyridylethanolamine beta3 adrenergic receptor agonists possessing a thiazole benzenesulfonamide pharmacophore.	Merck Research Laboratories
10915043	69	Substituted oxazole benzenesulfonamides as potent human beta3 adrenergic receptor agonists.	Merck Research Laboratories
10888325	90	Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents.	Merck Research Laboratories
10888324	48	Discovery of an orally bioavailable alkyl oxadiazole beta3 adrenergic receptor agonist.	Merck Research Laboratories
27239696	44	Uncoupling the Structure-Activity Relationships of ?2 Adrenergic Receptor Ligands from Membrane Binding.	Novartis Institutes For Biomedical Research
10780918	27	Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoroepinephrine: effect of stereochemistry on fluorine-induced adrenergic selectivities.	National Institute of Diabetes and Digestive and Kidney Diseases
10743949	76	(1,4-Benzothiazinyloxy)alkylpiperazine derivatives as potential antihypertensive agents.	Università
31625751	12	Synthesis, Purification, and Selective ?	Shandong University
31566384	134	Development of Chemical Entities Endowed with Potent Fast-Killing Properties against	Glaxosmithkline
30682248	15	Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs).	School of Pharmaceutical Sciences & The Fifth Affiliated Hospital
32342685	325	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D	National Institute of Neurological Disorders and Stroke
31151791	35	Development of covalent antagonists for ?1- and ?2-adrenergic receptors.	Friedrich-Alexander Universit£T Erlangen-N£Rnberg
31042379	96	Hybridization of ?-Adrenergic Agonists and Antagonists Confers G Protein Bias.	Friedrich-Alexander University Erlangen-N£Rnberg (Fau)
10406657	91	Potent, elective human beta3 adrenergic receptor agonists containing a substituted indoline-5-sulfonamide pharmacophore.	Merck Research Laboratories
30875219	254	Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D	University of North Carolina At Chapel Hill
10360736	2	S1319: a novel beta2-andrenoceptor agonist from a marine sponge Dysidea sp.	Kirin Brewery
10340609	15	L-770,644: a potent and selective human beta3 adrenergic receptor agonist with improved oral bioavailability.	Merck Research Laboratories
10201842	69	Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides.	Merck Research Laboratories
10201841	47	Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides.	Merck Research Laboratories
31913033	12	Fragment-to-Lead Medicinal Chemistry Publications in 2018.	Frontier Medicines
31298548	112	Probing the Existence of a Metastable Binding Site at the ?	University of Copenhagen
9873681	65	3-Pyridylethanolamines: potent and selective human beta 3 adrenergic receptor agonists.	Merck Research Laboratories
9873496	80	3-Pyridyloxypropanolamine agonists of the beta 3 adrenergic receptor with improved pharmacokinetic properties.	Merck Research Laboratories
31185168	144	Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.	Rti International
9871717	72	Discovery of L-755,507: a subnanomolar human beta 3 adrenergic receptor agonist.	Merck Research Laboratories
9871716	94	Potent, selective benzenesulfonamide agonists of the human beta 3 adrenergic receptor.	Merck Research Laboratories
30392952	49	Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent ?	Shenyang Pharmaceutical University
9572886	38	Synthesis and adrenergic activity of a new series of N-aryl dicyclopropyl ketone oxime ethers: SAR and stereochemical aspects.	University of Grenoble
9379432	36	Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign pr	Abbott Laboratories
31613617	195	Benzyl Phenylsemicarbazides: A Chemistry-Driven Approach Leading to G Protein-Biased Dopamine D	Friedrich-Alexander-Universit£T Erlangen-N£Rnberg
31620230	283	3-Amino-chromanes and Tetrahydroquinolines as Selective 5-HT	University of Minnesota Twin Cities
26590100	42	Discovery of benzamides as potent human ?3 adrenergic receptor agonists.	Merck And
26565745	165	Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.	Janssen Pharmaceutica
31223445	4	Computer-Aided Selective Optimization of Side Activities of Talinolol.	Goethe-University of Frankfurt
24326276	63	Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the ??-adrenergic receptor.	Medical University of Lublin
23954364	12	?2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis.	Medical University of South Carolina
7910217	36	The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists.	Universitá
21170122	84	Comparative 3D QSAR study on ?(1)-, ?(2)-, and ?(3)-adrenoceptor agonists.	National Institute of Pharmaceutical Education and Research
21075638	105	Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.	Drug Discovery Laboratory
17560786	48	Synthesis and evaluation of potent and selective beta3 adrenergic receptor agonists containing heterobiaryl carboxylic acids.	Glaxosmithkline
15887956	77	Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist.	Glaxosmithkline
15664848	43	3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.	Glaxosmithkline
10377236	15	2-Amino-4-benzyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridines: novel selective beta3-adrenoceptor agonists.	University of Tennessee
8809159	26	Iodinated analogs of trimetoquinol as highly potent and selective beta 2-adrenoceptor ligands.	University of Tennessee-Memphis
29751236	46	Synthesis and biological evaluation of ?	Shenyang Pharmaceutical University
29517238	3	Catecholic Isoquinolines from Portulaca oleracea and Their Anti-inflammatory and ?	Shandong University
29574204	54	Design and synthesis of aryloxypropanolamine as ?	East China Normal University
29364664	26	Binding-Site Compatible Fragment Growing Applied to the Design of ?	Philipps-University Marburg
2892936	21	Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.	Warner-Lambert
2875184	57	(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.	TBA
29066136	4	Ability of higenamine and related compounds to enhance glucose uptake in L6 cells.	Hokkaido University
2563296	38	A new series of tricyclic (aryloximino)propanolamines displaying very high selective beta 2-blocking properties.	Université
29851481	122	Discovery of ?-Adrenergic Receptors Blocker-Carbonic Anhydrase Inhibitor Hybrids for Multitargeted Antiglaucoma Therapy.	University of Florence
28355078	34	Discovery of Novel Indazole Derivatives as Orally Available?	Asahi Kasei Pharma
29589445	154	1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D	Universit£
1967313	21	Synthesis and beta-adrenergic antagonist activity of stereoisomeric practolol and propranolol derivatives.	University of California
1672155	14	Effect of fluorine substitution on the adrenergic properties of 3-(tert-butylamino)-1-(3,4-dihydroxyphenoxy)-2-propanol.	National Institute of Diabetes
1648138	33	Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands.	Universitá
1354264	19	Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino] propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent beta-adrenergic agonist virtually specific for beta 3 receptors. A promising antidiabetic and antiobesity agent.	American Cyanamid
1347318	52	Synthesis, cardiac electrophysiology, and beta-blocking activity of novel arylpiperazines with potential as class II/III antiarrhythmic agents.	Berlex Laboratories
19337725	43	Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo.	Case Western Reserve University
17221184	55	Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates.	Columbia University
16915381	31	WAY-100635 is a potent dopamine D4 receptor agonist.	Purdue University
16352709	44	Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.	Mcgill University
16051698	5	Characterization of isoprenaline- and salmeterol-stimulated interactions between beta2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells.	Institute of Cell Signaling
15999145	62	Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex.	Case Western Reserve University
21926995	79	Ligand discovery from a dopamine D3 receptor homology model and crystal structure.	University of California San Francisco
15131245	86	SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.	Sanofi-Synthelabo Recherche
14730417	62	Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.	UniversitÄT WÜRzburg
12784105	53	Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.	Case Western Reserve University
12761331	97	3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro.	Case Western Reserve University
12721338	61	N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.	Pudue Pharma Discovery Research
12649361	779	L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.	Case Western Reserve University
12431845	84	Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.	Eli Lilly
12388666	301	Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.	Institut De Recherches Servier
12192085	52	Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.	Case Western Reserve University
12110997	380	In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs.	WestfÄLische Wilhelms-UniversitÄ
11750183	29	Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.	Novartis Pharma
11750180	139	Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.	Eli Lilly
11512051	80	The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor.	Case Western Reserve University
11438309	51	The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound.	Janssen Research Foundation
11356907	15	Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.	Institut De Recherches Servier
11303056	2	Pharmacological characterization of KUR-1246, a selective uterine relaxant.	Kissei Pharmaceutical
11082457	63	S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.	Centre De Recherches De Croissy
11082453	77	ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.	Abbott Laboratories
10379421	134	Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.	TBA
9454810	72	SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.	Sanofi Recherche
9395253	17	Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.	Eli Lilly
9336327	37	The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.	Preclinical R & D, Astra Arcus
9225287	174	RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.	Roche Bioscience
9144661	24	BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats.	Smithkline Beecham Pharmaceuticals
8996185	121	Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.	SynthÉLabo Recherche
8935801	586	Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.	Janssen Research Foundation
8887981	72	A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.	Abbott Laboratories
8822531	111	Radioreceptor binding profile of the atypical antipsychotic olanzapine.	Eli Lilly
8788493	64	Novel discriminatory ligands for 5-HT2B receptors.	Smithkline Beecham Pharmaceuticals
8730737	23	Effects of the 5-HT2B receptor agonist, BW 723C86, on three rat models of anxiety.	Smithkline Beecham Pharmaceuticals
8584042	40	BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.	Boehringer Ingelheim Italia
8564266	77	Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.	Vrije Universiteit
8564196	35	Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.	Syntex Discovery Research
8386236	11	In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist.	Whitby Research
8093723	20	Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.	Dainippon Pharmaceutical
8012715	38	GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.	Glaxo Group Research
7921604	16	The effects of SB 204070, a highly potent and selective 5-HT4 receptor antagonist, on guinea-pig distal colon.	Smithkline Beecham Pharmaceuticals
7915318	120	Biochemical and pharmacological characterization of high-affinity trimetoquinol analogs on guinea pig and human beta adrenergic receptor subtypes: evidence for partial agonism.	Ohio State University
7910212	34	Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.	Yamanouchi Pharmaceutical
7523657	14	Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.	Eli Lilly
7518514	46	(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.	Abbott Laboratories
3790168	23	Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.	Wyeth Laboratories
2869639	166	Effects of remoxipride and some related new substituted salicylamides on rat brain receptors.	Astra LÄKemedel
2583244	35	Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study.	Virginia Commonwealth University
2537663	10	1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain.	Stanford University
1968985	56	Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.	Niigata College of Pharmacy
1352553	38	Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist.	University of North Carolina
8699	51	Beta adrenergic receptor binding in membrane preparations from mammalian brain.	TBA
19245211	9	Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.	Intervet Innovation
15655528	75	The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.	University of Nottingham
18783211	14	Synthesis of bivalent beta2-adrenergic and adenosine A1 receptor ligands.	Monash University